Brief: Neurogene Reports Positive Interim Efficacy Data From First Four Low-Dose Pediatric Participants In Ngn-401 Gene Therapy Clinical Trial For Rett Syndrome

Neurogene

11/11/2024 21:46

Nov 11 (Reuters) - Neurogene Inc  NGNE.O :
    * NEUROGENE REPORTS POSITIVE INTERIM EFFICACY DATA FROM
FIRST FOUR
LOW-DOSE PEDIATRIC PARTICIPANTS IN NGN-401 GENE THERAPY CLINICAL
TRIAL FOR RETT SYNDROME
    * NEUROGENE INC - ALL PARTICIPANTS SHOW 2-POINT IMPROVEMENT
IN
CGI-I SCALE
    * NEUROGENE INC - PARTICIPANTS SHOW 28-52% IMPROVEMENT IN
RETT
SYNDROME BEHAVIOR QUESTIONNAIRE
    * NEUROGENE INC - LOW-DOSE NGN-401 WELL-TOLERATED WITH
FAVORABLE
SAFETY PROFILE
    * NEUROGENE INC - GAINS FDA ALIGNMENT ON POTENCY ASSAY
STRATEGY
FOR NGN-401
    * NEUROGENE INC - TO HALT NGN-101 CLN5 BATTEN DISEASE GENE
THERAPY
PROGRAM
    * NEUROGENE INC: PLANS TO PROVIDE AN UPDATE OF
REGISTRATIONAL
TRIAL DESIGN IN H1 2025

Source text:  ID:nBw8xG8Vka 
Further company coverage:  NGNE.O 

 ((Reuters.Briefs@thomsonreuters.com;))